Arthritis
Drug research and approvals for arthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,059 studies of arthritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 123 drug trials for it since 2013, FDA has 11 approved and 15 open orphan designations naming it, and the EU has 51 authorised medicines for it.
- Recruiting worldwide: 1,059
- Trials authorized in Canada: 123
- FDA orphan approvals: 11
- EU medicines: 51
- Anti-Adalimumab Antibodies in Children With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious UveitisNCT07947615 · Not reported · Meyer Children's Hospital IRCCS · starts Oct 7, 2026
- CAPN12 Gene Expression as a Molecular DiscriminatorNCT07946497 · Not reported · South Valley University · starts Oct 1, 2026
- Dual-targeting of B & T Cell Pathways Evaluation TrialNCT07946367 · Phase 1 / Phase 2 · Diabetes Free, Inc. · starts Dec 1, 2026
- ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute…NCT07938164 · Phase 4 · ANI Pharmaceuticals · starts Jan 28, 2026
- Periodontitis in Patients With OsteoarthritisNCT07935421 · Not reported · University of Zagreb · starts Jan 15, 2025
- Arthrocentesis vs Observation Study for Acute ACL TearsNCT07929922 · Not applicable · Ohio State University · starts Aug 1, 2026
- A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous…NCT07920861 · Phase 1 · Huabo Biopharm Co., Ltd. · starts Jan 19, 2026
- Effects of Virtual Reality Environments on Walking in Adults With and Without Knee OsteoarthritisNCT07920120 · Not applicable · University of Primorska · starts Aug 26, 2026
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA…NCT07919678 · Phase 3 · Pfizer · starts Oct 26, 2026
Approved 13
- MethotrexateDihydrofolate reductase inhibitor
- AcetaminophenCyclooxygenase inhibitor
- IbuprofenCyclooxygenase inhibitor
- NaproxenCyclooxygenase inhibitor
- LidocaineSodium channel alpha subunit blocker
- AdalimumabTNF-alpha inhibitor
- PrednisoneGlucocorticoid receptor agonist
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- CapsaicinVanilloid receptor opener
- AspirinCyclooxygenase inhibitor
- Penicillin vBacterial penicillin-binding protein inhibitor
- Methyl salicylate
- Camphor
Phase 3 1
- EtanerceptTNF-alpha inhibitor
How its trials ended
3,882 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 1,101 whose ending is known, 59% met their primary endpoint, 6% missed it and 35% stopped early.
- Completed, result not reported1,68543%
- Met its primary endpoint64817%
- Ongoing61716%
- Status unknown47912%
- Stopped: other or unclear1825%
- Stopped: enrollment or feasibility862%
- Missed its primary endpoint692%
- Stopped: sponsor or business decision672%
- Stopped: lack of efficacy381%
- Stopped: funding7<1%
- Stopped: safety4<1%
| Nov 13, 2026 | A phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-8690 in participants with rheumatoid arthritisMK-8690 | Merck & Co. (MSD) | Pending |
| Aug 11, 2026 | A randomized, double-blind, placebo-controlled, multicenter phase 2a/b study assessing the efficacy, safety and tolerability of DDY391 in participants with…DDY391 | Novartis Pharmaceuticals | Pending |
| May 13, 2026 | A phase 3, multicenter, long-term extension study to evaluate the long-term safety, tolerability, and efficacy of zasocitinib (TAK-279) in subjects with active…Zasocitinib (TAK-279) | Takeda Pharmaceuticals USA | Pending |
| Apr 13, 2026 | A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with psoriatic arthritisTulisokibart (MK-7240) | Merck & Co. (MSD) | Ongoing |
| Nov 7, 2025 | A multicentre, parallel-group, phase II, randomised, double-blind, 4 arm study to evaluate efficacy and safety of AZD1163 in participants with moderately-to…AZD1163 | AstraZeneca Pharmaceuticals | Ongoing |
| Aug 22, 2025 | A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with rheumatoid arthritisTulisokibart (MK-7240) | Merck & Co. (MSD) | Ongoing |
| Aug 19, 2025 | A phase 2, multicenter, platform study of targeted therapies for the treatment of adult subjects with moderately to severely active rheumatoid arthritisLutikizumab (ABT-981) / Ravagalimab (ABBV-323) | AbbVie | Ongoing |
| Apr 11, 2025 | A phase 2 multicenter, randomized, platform study of targeted therapies for the treatment of adult subjects with active psoriatic arthritisLutikizumab (ABT-981) / Risankizumab (ABBV-066) | AbbVie | Ongoing |
| Mar 5, 2025 | A multi-center, randomized, double-blind, and placebo-controlled phase 3 study to evaluate the efficacy and safety of zasocitinib (TAK-279) in subjects with…Zasocitinib (TAK-279) | Takeda Pharmaceuticals USA | Ongoing |
| Feb 7, 2025 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of JNJ-77242113 for the treatment of…Icotrokinra (JNJ-77242113) | Johnson & Johnson | Ongoing |
| Apr 26, 2024 | RinvoqTreatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response… | AbbVie, Inc. | Approved |
| Sep 29, 2020 | Simponi Aria®Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older | Janssen Research & Development, LLC | Approved |
| Jun 16, 2020 | CanakinumabILARIS is indicated for the treatment of active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile… | Novartis Pharmaceuticals Corporation | Approved |
| May 11, 2018 | ActemraACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in… | Genentech, Inc. | Approved |
| Apr 25, 2017 | XatmepManagement of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic… | Silvergate Pharmaeuticals, Inc. | Approved |
| Sep 30, 2014 | HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and… | AbbVie Inc. | Approved |
| May 9, 2013 | IlarisTreatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older. | Novartis Pharmaceuticals Corporation | Approved |
| Apr 29, 2013 | ActemraACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in… | Genentech, Inc. | Approved |
| Feb 21, 2008 | HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and… | AbbVie Inc. | Approved |
| Aug 11, 2005 | MobicFor relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or… | Avondale Pharmaceuticals | Approved |
| May 27, 1999 | EnbrelReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older | Immunex Corporation | Approved |
| Aug 16, 2017 | UpadacitinibTreatment of pediatric systemic juvenile idiopathic arthritis | AbbVie, Inc. | Designated |
| Jul 3, 2017 | Tadekinig alfaTreatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA) | AB2 Bio Ltd | Designated |
| Jan 11, 2017 | Protoplasmic protein matrix, omega-3 fatty oils, vitamins,…Treatment of juvenile rheumatoid arthritis. | Leonard S. Girsh, MD | Designated |
| Jan 5, 2017 | Celecoxib oral liquid suspensionTreatment of pediatric juvenile idiopathic arthritis | NuBioPharma, LLC | Designated |
| Nov 12, 2026 | InijaqTofacitinib · generic | Gedeon Richter Plc. | EMA ↗ |
| Apr 27, 2026 | TuyoryTocilizumab · biosimilar | Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.) | EMA ↗ |
| Apr 23, 2026 | FubelvEtanercept · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Feb 10, 2026 | GotenfiaGolimumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Nov 17, 2025 | GobivazGolimumab · biosimilar | Advanz Pharma Limited | EMA ↗ |
| Feb 14, 2025 | AvtozmaTocilizumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
| Sep 19, 2024 | ItuxrediRituximab · biosimilar | Reddy Holding GmbH | EMA ↗ |
| Jun 20, 2024 | Tosmova (previously Tocilizumab STADA and Tofidence)Tocilizumab · biosimilar | STADA Arzneimittel AG | EMA ↗ |
| Apr 19, 2024 | Apremilast AccordApremilast · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 15, 2023 | TyenneTocilizumab · biosimilar | Fresenius Kabi Deutschland GmbH | EMA ↗ |
| Mar 24, 2023 | SotyktuDeucravacitinib | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Nov 15, 2021 | HukyndraAdalimumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Nov 12, 2021 | LibmyrisAdalimumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Aug 20, 2021 | BimzelxBimekizumab | UCB Pharma S.A. | EMA ↗ |
| Feb 11, 2021 | YuflymaAdalimumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA